MedPath

Photobiomodulation Effects on Pain, Edema, Paresthesia and Bone Regeneration After Maxillar Surgical Disjunction

Phase 2
Conditions
Maxillary Diseases
Interventions
Radiation: Photobiomodulation
Radiation: Placebo Photobiomodulation
Registration Number
NCT03814525
Lead Sponsor
University of Nove de Julho
Brief Summary

The objective of the present study will be to evaluate the efficacy of photobiomodulation (PBM) with LED in pain control, facial edema, paresthesia, bone repair and quality of life arising after maxillar surgical disjunction (MSD). A randomized, double-blind, placebo-controlled clinical trial involving 72 participants aged 18 to 45 years, who search the Service of Oral Maxillofacial Surgery and Traumatology of the Mandaqui Hospital Complex to undergo MSD, attend to the eligibility criteria and agree to participate. Surgeries will be conducted by three oral maxillofacial surgeons who will perform all surgical procedures, two examiners (who will perform pre and post-surgical evaluations, blinded to the experimental group) and another researcher who will perform the LED application. Before the surgeries, facial measures, radiographic examinations, tests of facial and oral sensitivity and the evaluation of the level of anxiety of all the participants will be carried out. Immediately after the surgeries, the participant will be inserted into the placebo group or the LED group, according to block randomization defined previously. In the LED group, the participants will receive PBM with an extraoral device (660 and 850 nm with 6J per point) and an intraoral one (660 nm with 2J per point) and in the control group the participants will be attended in the same way, but with the LED devices kept off. The applications will be in the immediate postoperative period, 1, 2, 7, 14, 30, 60, 90 and 120 days after the end of the surgeries, when the evaluations will also be performed. Facial measurements, extra and intraoral sensitivity, pain and bone repair will be evaluated. Secondarily, the data regarding the occurrence of headache; otalgia; nausea; bruise; nasolacrimation; epistaxis; dysphagia; systemic and superficial temperature in the operated region; use of analgesics and anti-inflammatories; anxiety and impact of oral health on the participants' quality of life will be computed.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
72
Inclusion Criteria
  • Transverse maxillary deficiency ˃ of 5 mm with bilateral posterior crossbite and indication for surgical maxillary disjunction.
  • Agree to participate in the study after reading and signing the Term of Consent for Participation in Clinical Research.
Exclusion Criteria
  • Transverse maxilla deficiency, with unilateral posterior crossbite.
  • Local or systemic alterations that contraindicate surgical intervention or hinder the postoperative period.
  • Smokers.
  • Display photo sensitivity history.
  • Possess systemic diseases, chronic pain or neurological and psychiatric disorders.
  • Have been using anti-inflammatories, analgesics or bisphosphonates in the past 15 days.
  • Pregnant.
  • Breastfeeding.
  • Participants who present any type of complication during surgery (hemorrhage, operative difficulty), as these cases will not be in the expected pattern for these surgeries. These data will not be part of the statistical analysis but will be described and discussed, as well as possible adverse effects.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Photobiomodulation groupPhotobiomodulationPBM will be applied after the surgeries with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
Control groupPlacebo PhotobiomodulationParticipants will be attended in the same way as the PBM group. The person who is responsible for the application of the PMB will simulate the irradiations by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off.
Primary Outcome Measures
NameTimeMethod
Change in PainAfter 1, 2, 7 and 14 days of surgeries.

A Visual Analog Scale (VAS) will be printed on the patient evaluation form and the subjects will be instructed by the evaluator to mark a point in the line of 10 cm, indicating the intensity of their pain after 1,2, 7 and 14 days of the surgeries. For the NRS-101 scale, the evaluators will ask patients to assign a number between 0 (no pain) and 100 (worst possible pain) that best represents the pain they are currently experiencing after 1, 2, 7 and 14 days of surgeries.

Change in postoperative bone repairAfter 30, 60, 90 and 120 days of surgeries.

The optical density (OD) of the alveolar bone in the anterior region of the palatine suture, in each experimental period, will be calculated and compared with that obtained in the preoperative radiographic examination.

Change in EdemaAfter 1, 2, 7 and 14 days of surgeries.

Using a flexible plastic millimeter tape (0.5mm precision), five facial measurements will be taken corresponding to the distances between the points listed below as described by Ristow et al. (2013).

Line A - posterior tragus point to the most lateral point of the labial commissure Line B - tragus posterior point to pogonium Line C - posterior tragus point to the lateral corner of the eye Line D - lateral corner of eye to lowest point of jaw angle Line E - lower point of the angle of the mandible (gonio) to the middle of the nasal bone

Change in intra and extraoral sensitivityAfter 7, 30, 60, 90 and 120 days of surgeries.

The evaluation of extra and intraoral sensitivity will be performed in 6 regions: below the lower eyelid, cheek, nose wing, upper lip, oral buccal mucosa and oral palatal mucosa on both sides. The tests will be performed sequentially, with a 2 to 3 minute interval between each. The participant will receive instructions on the tests that will be initially performed on the back of his hand so he can become familiar.

Secondary Outcome Measures
NameTimeMethod
Presence of otalgiaAfter 1, 2, 7 and 14 days of surgeries.

Patients will answer yes or not, to indicate whether they had otalgia in the examined periods.

Presence of dysphagiaAfter 7 and 30 days of surgeries.

The evaluation of dysphagia will be performed after 7 and 30 days by questioning and classification on a numerical scale in which:

(0) total absence of dysphagia;

1. dysphagia to solid foods

2. dysphagia to any liquid or solid food

Postoperative quality of lifeAfter 7 and 30 days of surgeries.

Patients will answer yes or no to the following questions:

1. Are you maintaining your social activities normally?

2. Are you working / studying normally?

3. Are you maintaining your normal diet?

4. Do you have difficulty swallowing because of the surgery?

5. Do you have difficulty in tasting food?

6. Can you chew on the sides?

7. Do you have trouble sleeping because of the surgery?

8. Did you have trouble speaking because of the surgery?

9. Has your appearance changed because of the surgery?

10. Do you feel sick from the surgery?

Change in temperatureAfter 1, 2, 7 and 14 days of surgeries.

The temperature will be measured locally (on both sides) and systemically. Local measurements will be measured using an infrared digital thermometer in the right and left cheek region and anterior nasal spine. The systemic temperature will be measured in the frontal region of the patient in the median position 3 cm above the glabella.

Presence of bruisesAfter 1, 2, 7 and 14 days of surgeries.

The presence of hematoma/ecchymosis will be evaluated by measuring the largest diameter of the colorimetric changes on the right and left side. The measure will be performed by the examiners who will classify the occurrence of this result into four categories: 1) none; 2) larger diameter smaller than 4 cm; 3) larger diameter between 4 and 10 cm, and 4) larger diameter greater than 10 cm.

Presence of nasolacrimationAfter 1, 2, 7 and 14 days of surgeries.

Patients will answer yes or not, to indicate whether they had nasolacrimation in the examined periods.

Presence of headacheAfter 1, 2, 7 and 14 days of surgeries.

Patients will answer yes or not, to indicate whether they had headaches in the examined periods.

Presence of nauseaAfter 1, 2, 7 and 14 days of surgeries.

Patients will answer yes or not, to indicate whether they had nausea in the examined periods.

Presence of nose bleedingAfter 1, 2, 7 and 14 days of surgeries.

Patients will answer yes or not, to indicate whether they had nose bleeding in the examined periods.

Trial Locations

Locations (1)

Conjunto Hospitalar do Mandaqui

🇧🇷

São Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath